Access to Risdiplam in Scotland: Your Views
02 September 2021
Please let us know your views so that we can pass them on to the Scottish Medicines Consortium (SMC).
As you have may have heard, the Scottish Medicines Consortium (SMC) has now started its review of whether to recommend risdiplam for funding by the NHS in Scotland. Patient groups have been invited to make submissions by 4th October 2021. SMA UK and MDUK are writing their submission jointly, as we’ve done for other treatments in both Scotland and England.
We want our submission to reflect the views of people in Scotland who are affected by SMA, including those who are bereaved by SMA, so we’re putting out this short survey with a closing date of Thursday 16th September.
We will also draw on the work we have done already advocating for access to risdiplam in England:
- Our autumn 2020 community surveys and submission to NICE – of the 137 survey responses, 10 were from people from Scotland.
- Our June 2021 consultation response to NICE which included results of UK-wide surveys on the impact of SMA (including January 2018 survey results from Scotland).
- As there have been further clinical trial results since the original survey and submission, we will refer to the latest updates if appropriate, these are here.
We look forward to hearing from you. Thank you.
